Description: Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers offers products and solutions for the diagnosis and treatment of chronic eye diseases; and systems and consumables for refractive surgery. This segment also provides slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras used for the examination of the retina in hospitals and practices; and equipment for functional diagnostics. In addition, this segment offers surgical microscopes, biometers, and phacoemulsification or vitrectomy devices; and intraocular lenses for cataract patients. The Microsurgery segment offers visualization solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
Home Page: www.zeiss.de/meditec-ag/home.html
Goschwitzer Strasse 51-52
Jena,
07745
Germany
Phone:
49 3641 220 115
Officers
Name | Title |
---|---|
Mr. Justus Felix Wehmer | CFO & Member of the Management Board |
Dr. Markus Weber | Pres, CEO & Chairman of Management Board |
Mr. Sebastian Frericks | Director of Investor Relations |
Mr. Martin Wiechmann | Head of the Planetarium Bus. Unit |
Mr. Mike Wang | Head of Marketing - Shanghai |
Mr. Steven C. Schallhorn M.D. | Chief Medical Officer for Global Ophthalmic Devices |
Mr. Andrew Chang | Head of Sales for Ophthalmic Devices & Pres of Carl Zeiss Meditec, Inc. |
Laurie Ferguson | Head of Global Communications Ophthalmic Devices |
Dr. Euan S. Thomson Ph.D. | Pres of Ophthalmic Devices & Head of the Ophthalmic Devices Strategic Bus. Unit |
Exchange: XETRA
Country: DE
Currency: Euro (€)
Forward PE: | 39.2157 |
---|---|
Trailing PE: | 48.9416 |
Price-to-Book MRQ: | 6.5328 |
Price-to-Sales TTM: | 5.5629 |
IPO Date: | |
Fiscal Year End: | September |
Full Time Employees: | 4224 |